The prognostic value of a trend in modified SOFA score forpatients with hematological malignancies in the intensivecare unit by Demandt, Astrid M. P. et al.
  
 University of Groningen
The prognostic value of a trend in modified SOFA score forpatients with hematological
malignancies in the intensivecare unit
Demandt, Astrid M. P.; Geerse, Daniel A.; Janssen, Bram J. P.; Winkens, Bjorn; Schouten,
Harry C.; van Mook, Walther N. K. A.
Published in:
European Journal of Haematology
DOI:
10.1111/ejh.12919
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Demandt, A. M. P., Geerse, D. A., Janssen, B. J. P., Winkens, B., Schouten, H. C., & van Mook, W. N. K.
A. (2017). The prognostic value of a trend in modified SOFA score forpatients with hematological
malignancies in the intensivecare unit. European Journal of Haematology, 99(4), 315-322.
https://doi.org/10.1111/ejh.12919
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Eur J Haematol. 2017;99:315–322.	 	 	 | 	315wileyonlinelibrary.com/journal/ejh
Accepted: 20 June 2017
DOI: 10.1111/ejh.12919
O R I G I N A L  A R T I C L E
The prognostic value of a trend in modified SOFA score 
for patients with hematological malignancies in the 
intensive care unit
Astrid M.P. Demandt1  | Daniël A. Geerse2 | Bram J.P. Janssen3 | Bjorn Winkens4 |  
Harry C. Schouten1 | Walther N.K.A. van Mook5
1Division of Hematology, Department 
of Internal Medicine, GROW, Maastricht 
University Medical Center, Maastricht, The 
Netherlands
2Division of Nephrology, Department 
of Internal Medicine, Bravis Hospital, 
Roosendaal, The Netherlands
3Department of Anaesthesiology, University 
Medical Center Groningen, Groningen, The 
Netherlands
4Department of Methodology and 
Statistics, CAPHRI, Maastricht University, 
Maastricht, The Netherlands
5Department of Intensive Care 
Medicine, Maastricht University Medical 
Center, Maastricht, The Netherlands
Correspondence
Astrid M.P. Demandt, Division of Hematology, 
Department of Internal Medicine, Maastricht 




Background: Patients with hematological malignancies admitted to an intensive care 
unit (ICU) have a poor prognosis. The Sequential Organ Failure Assessment (SOFA) 
score is used to monitor patients on the ICU. Little is known about the value of this 
score in hematology patients. Therefore, the prognostic value of the SOFA score and 
a modified hematological SOFA score (SOFAhem) was studied.
Methods: Patients with hematological malignancies admitted to the ICU between 
1999 and 2009 were analyzed in a retrospective cohort study. The SOFAhem score 
was defined as the original SOFA score omitting the coagulation and neurological 
parameters.
Results: In 149 admissions, ICU mortality was 52%. Mortality was significantly associ-
ated with higher SOFA and SOFAhem scores on admission, and trend in SOFAhem 
scores. An unchanged and increased SOFAhem score compared to decreasing 
SOFAhem scores was associated with a higher mortality rate (53% resp 67% resp 25%).
Conclusions: Trends in SOFA or SOFAhem score are both suitable as prognostic param-
eter. The trend in SOFAhem score seems to be independently related to mortality in 
hematological patients admitted to the ICU, and because of the higher odds ratios and 
lower P- values compared to the SOFA score, it is probably stronger related to mortality 
than the classical score, but its prognostic value should be tested in a larger cohort.
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1  | INTRODUCTION
Outcome in patients with a hematological malignancy has improved 
over the last decades thanks to developments in therapeutic op-
tions, such as intensive chemotherapy regimens, use of novel agents 
like targeted drugs and stem cell transplantation on the one, and im-
provement of supportive measures on the other hand.1 Concurrently, 
the incidence of life- threatening complications of these therapies 
has increased as well, often requiring transfer to an intensive care 
unit (ICU).2 Patients with a hematological malignancy admitted to 
an ICU are often assumed to have a poor prognosis, 3 with reported 
ICU mortality ranging from 34% to 68%.3–13 Factors contributing to 
the prognosis of patients with hematological malignancies admitted 
to an ICU have been investigated by multiple studies. Most of these 
found that short- term prognosis is mainly determined by severity of 
illness, but not by the underlying disease itself or the indication for ICU 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any 
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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admission.14 Severity of illness was mainly reflected by higher organ 
failure scores and the need for mechanical ventilation and vasopres-
sors. This associated poor outcome sometimes results in reluctance 
to admit this subgroup of patients to the ICU. More recent studies 
however show a better survival after ICU admission and, even more 
important, that the long- term health- related quality of life (HRQoL) is 
not affected.11,15,16
It is difficult to predict a patient’s prognosis based solely on pa-
rameters that are available at ICU admission. For this reason, less re-
strictive admission policies have been advocated, often resulting in 
a trial of ICU admission and treatment, during which unlimited care 
is provided for a limited period of time.17,18 After an arbitrary period 
of 3- 7 days, a decision is then made whether or not to continue ICU 
treatment. Consequently, after a few days of ICU treatment there is 
a need for parameters which contribute to evaluate the prognosis at 
that time. For this purpose, changes in organ failure scores, such as the 
Sequential Organ Failure Assessment (SOFA) score19 (Table 1), during 
ICU stay have been studied.3,10,20
The SOFA score was initially designed to study organ failure in 
patients with sepsis (sepsis- related organ failure assessment) admit-
ted to the intensive care unit, using six categories (see Materials and 
Methods). As the score was not specific for sepsis, it was later changed 
into the Sequential Organ Failure Assessment. A recent study devel-
oped a modified hematological SOFA score taking into account recent 
infection before admission, and this modified score was better for dis-
criminating survivors from non- survivors than the unmodified score.21
For several reasons, we hypothesize that the conventional SOFA 
score is not a good reflection of the current problem that caused the 
transfer to the ICU. First, as platelets are an important part of the 
SOFA score, it can be envisaged that the thrombocytopenia in patients 
with a hematological malignancy admitted to the ICU is an expression 
of the underlying hematological disease rather than a reflection of the 
current problem. Second, recent studies evaluated a modified SOFA 
score in medical and surgical patients, omitting the neurological score 
and showed this score was significantly associated with mortality.22,23 
The neurological score was excluded as the results of the neurological 
evaluation are most commonly influenced by the use of sedatives. The 
recent study in hematological patients only calculated the modified 
score on admission and because of that we did not involve this score.21
In the present study, the classical SOFA score was consequently 
changed into the modified hematological SOFA score (SOFAhem), omit-
ting the coagulation and central nervous system parameters (Table 1), 
and furthermore the trend in SOFA was studied in a larger cohort be-
cause the study of Geerse et al.10 suggested that the change in SOFA 
score during the stay on the ICU could be helpful in decision- making 
about further treatment. We also studied the trend in SOFAhem.
2  | MATERIALS AND METHODS
All patients with hematological malignancies that were admitted to 
the ICU of the Maastricht University Medical Center (MUMC) in 
Maastricht, the Netherlands, were retrospectively included between 
December 1999 and November 2009. A cohort of patients previously 
studied was part of this population.10 All hematological patients who 
were transferred from the hematology ward to the ICU or hematologi-
cal patients who were directly admitted to the ICU through the emer-
gency department were identified. Readmissions were not evaluated. 
Decisions to admit a patient to the ICU were made together by the 
intensivists and hematologists.
TABLE  1 SOFA score
SOFA score 1 2 3 4
Respirationa
PaO2/FiO2 mm Hg <400 <300 <200 with respiratory 
support
<100 with respiratory 
support
Coagulation
Platelets×103/mm3 <150 <100 <50 <20
Livera
Bilirubin, mg/dL (μmol/L) 1.2- 1.9 (20- 32) 2.0- 5.9 (33- 101) 6.0- 11.9 (102- 204) >12.0 (>204)
Cardiovasculara







Glasgow coma score 13- 14 10- 12 6- 9 <6
Renala
Creatinine, mg/dL (μmol/L) or 
urine output
1.2- 1.9 (110- 170) 2.0- 3.4 (171- 299) 3.5- 4.9 (300- 440) or 
<500 mL/d
>5.0 (>440) or 
<200 mL/d
SOFA, sequential organ failure assessment.
J. Vincent Intensive Care Medicine 1996.
aIncluded in SOFAhem.
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Because of the retrospective design of the study, approval of the 
study, by the institutional review board (IRB), was not needed.
The following data were documented: demographic character-
istics; type and status of hematological malignancy; therapy charac-
teristics and therapy- related complications, such as the presence and 
duration of neutropenia and graft- vs- host disease; indication for ICU 
admission; clinical and laboratory parameters; the need for cardiopul-
monary resuscitation, mechanical ventilation, vasopressor/inotropic 
drugs, and renal replacement therapy; the presence of bacteremia. 
Using these data, the Acute Physiology And Chronic Health Evaluation 
II (APACHE II) score was calculated, as well as the Sequential Organ 
Failure Assessment (SOFA) and modified SOFAhem score on days 1, 3, 
5, and 7 after admission. The original SOFA (Table 1) score includes 
parameters on six organ systems (respiratory, cardiovascular, neuro-
logical, hepatic, renal, and coagulation system, respectively, PaO2, hy-
potension, Glasgow coma score, bilirubin, creatinine, and platelets).19 
The SOFAhem score was defined as the sum of the four components 
omitting the coagulation and neurological parameters.
Patients were grouped based on trend in SOFA and SOFAhem score 
(decreased, increased, or unchanged), with decrease and increase de-
fined	as	≥2	points	change.	The	trend	in	SOFA	and	SOFAhem score was 
only calculated between day 1 and day 3, because of a decrease of 
data availability over time due to transfer back to the hematology ward 
or death.
Disease status was based on the last available bone marrow biopsy 
or imaging data and was classified as previously untreated disease, 
partial or complete remission or progressive disease. Neutropenia was 
defined as an absolute neutrophil count<0.5×109/L.
Continuous variables were expressed as mean±standard devia-
tion or median and interquartile range (IQR). Categorical variables 
were expressed as total numbers and percentages. To investigate 
the difference in patient characteristics between ICU survivors and 
non- survivors, or between time- periods (1999- 2004 vs 2005- 2009), 
Pearson’s Chi- square or Fisher’s exact test for categorical variables 
and independent samples t test or Mann- Whitney U test for continu-
ous variables were used where appropriate. The effect of well- known 
factors associated with ICU mortality and statistically significant dif-
ferences between ICU survivors and non- survivors were assessed 
using univariable logistic regression analysis. Using multivariable logis-
tic regression analyses, the effect of the trend in SOFA and in SOFAhem 
on ICU mortality was corrected separately for invasive mechanical 
ventilation, vasopressor/inotropic medication, and APACHE II, which 
are the most important risk factors for ICU mortality.14 All analy-
ses were performed with IBM SPSS Statistics for Windows (Version 
22.0.0; IBM Corp, Armonk, NY, USA). P-	values≤.05	were	considered	
statistically significant.
3  | RESULTS
In this study, 174 admissions were seen in 149 different patients. 
Of these, 75 patients (86 admissions) were previously described in 
the study of Geerse et al.10 Nineteen patients were readmitted once, 
three were readmitted twice. Of those patients, only the first admis-
sion was evaluated. Table 2 provides baseline characteristics divided 
by ICU survival. Mean age at ICU admission was 54±13 year, and 92 
patients (62%) were male. Median duration of ICU stay was 4 days 
(IQR 2- 10 days). ICU mortality was 52%, and in- hospital mortality was 
60%. Mortality after 1 year was 71%. ICU mortality improved slightly 
over time, being 56% from 1999 to 2004 and 50% from 2005 to 2009. 
The mean APACHE II scores for the two groups on admission were 
equal (29±7.8 vs 29±7.1).
Acute myeloid leukemia was the most common hematological ma-
lignancy diagnosed (40%), followed by non- Hodgkin lymphoma (31%). 
In 101 patients (68%), chemotherapy was administered within 30 days 
prior to ICU admission and 60 patients (40%) had undergone a stem 
cell transplantation and the majority (60%), an allogeneic transplanta-
tion. Neutropenia at ICU admission was seen in 84 patients (56%). The 
most common indications for ICU admission were respiratory insuffi-
ciency (47% of patients) and sepsis (26% of patients). Mean APACHE II 
score was 29.5±7.4, and mean SOFA score at admission was 10.9±3.4. 
Ninety- eight patients (66%) were mechanically ventilated and 99 pa-
tients (66%) received vasopressor or inotropic therapy within 24 hours 
after ICU admission.
Differences in ICU survivors and non- survivors are displayed 
in Table 3. ICU survivors had significantly lower APACHE II scores 
(26.3±6.5 vs 32.4±6.9), SOFA scores (9.5±3.2 vs 12.2±3.2), and 
SOFAhem scores at admission (6.3±2.5 vs 8.1±2.5). These dif-
ferences were also seen for maximum SOFA score (10.4±3.4 vs 
14.0±3.3) and maximum SOFAhem score (6.8±2.7 vs 9.2±2.7) during 
the first week of ICU stay. Vasopressor/inotropic therapy, mechan-
ical ventilation, and bacteremia were more common in ICU non- 
survivors, as well as the need for resuscitation. These were also 
statistically significant.
The indication for ICU admission, type of underlying disease, and 
disease status did not differ between ICU survivors and non- survivors; 
neither did the presence and duration of neutropenia, neutropenia re-
covery on the ICU, and the presence of graft- vs - host disease.
SOFA scores were available on day 1 and day 3 for 103 patients. 
The trend in SOFA and SOFAhem is shown in Table 3. Patients with 
an unchanged or increased SOFA score had a higher ICU mortality 
(57 resp. 55%) as compared to patients with a decreased SOFA score 
(30%). For the patient group with an increased score, this difference 
was not significant, and for the patients with an unchanged score, it 
was significant. The SOFAhem showed that patients with an increased 
score had the highest mortality (67%), but patients with an unchanged 
SOFAhem score also had a significantly worse outcome (53%) than pa-
tients with a decreased SOFAhem score (25%, Table 3).
Table 4 shows the univariable logistic regression analysis of factors 
associated with ICU mortality. Patients without the history of a stem 
cell transplantation and patients with an allogeneic stem cell transplan-
tation had significantly higher ICU mortality compared to autologous 
transplantation. The APACHE II score, the SOFA score at admission 
and an unchanged SOFA score, and an increased or an unchanged 
SOFAhem score were also significantly associated with ICU mortality. 
Furthermore, mechanical ventilation, cardiopulmonary resuscitation, 
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TABLE  2 Patient characteristics and variables and ICU mortality
Patient characteristics Total (n=149)
ICU survivors  
(n=72; 48%)




Age (mean±SD) 54±13 54±13 54±13 .83
Gender
Male 92 62% 47 65% 45 58% 49 .41
Female 57 38% 25 35% 32 42% 56
Hematological malignancy
Acute leukemia 60 40% 23 32% 37 48% 62 .15
 (non)Hodgkin lymphoma 46 31% 25 35% 21 27% 46
Other 43 29% 24 33% 19 25% 44
Disease status
Previously untreated 54 36% 28 39% 26 34% 48 .69
Partial/complete remission 64 43% 31 43% 33 43% 52
Progressive/refractory 31 21% 13 18% 18 23% 58
CT in last 30 d
Yes 101 68% 51 71% 50 65% 50 .49
No 48 32% 21 29% 27 35% 56
Stem cell transplantation (SCT)
No 89 60% 42 58% 47 61% 53 .07
Autologous 24 16% 17 24% 7 9% 29
Non- myeloablative allogeneic 18 12% 7 10% 11 14% 61
Myeloablative allogeneic 18 12% 6 8% 12 16% 67
Days between last CT and ICU 
admission (median, IQR)
12 (2- 30) 13 (2- 25) 12 (3- 48) .88
Neutropenia on ICU admission
Yes 84 56% 38 53% 46 60% 55 .41
No 65 44% 34 47% 31 40% 48
Neutropenia >21 d on ICU admission
Yes 22 26% 11 29% 11 24% 50 .63
No 62 74% 27 71% 35 76% 56
Indication for ICU admission
Respiratory failure 70 47% 32 44% 38 49% 54 .22
Sepsis 38 26% 17 24% 21 27% 55
Heart failure 15 10% 9 12% 6 8% 40
Postresuscitation 11 7% 3 4% 8 10% 73
Neurological 6 4% 4 6% 2 3% 33
Other 9 6% 7 10% 2 3% 22
Graft- vs - host disease
Yes 20 13% 8 11% 12 16% 60 .48
No 129 87% 64 89% 65 84% 50
Organ failure scores
APACHE II (mean±SD) 29.5±7.4 26.3±6.5 32.4±6.9 <.001
SOFA score day 1 (mean±SD) 10.9±3.4 9.5±3.2 12.2±3.2 <.001
SOFAhem day 1 (mean±SD) 7.2±2.6 6.3 ±2.5 8.1 ±2.5 <.001
SOFA max in first week 
(mean±SD)
12.2±3.8 10.4±3.4 14±3.3 <.001
SOFAhem max in first week 
(mean±SD)
8.1±2.9 6.8±2.7 9.2±2.7 <.001
(Continues)
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and the need for vasopressor/inotropic therapy were associated with 
worse outcome.
As described before, the trend in SOFA and SOFAhem score was 
corrected separately for invasive mechanical ventilation, vasopressor/
inotropic therapy, and APACHE II. Patients with an unchanged or in-
creased SOFA score had a significant worse outcome than patients 
with a decreased SOFA score, only when correcting for vasopressor/
inotropic medication an increasing score did not show significance. 
The trend in SOFAhem score was independently associated with mor-
tality (Table 5). In this analysis, the classical and modified score were 
both associated with poor patient outcome, but the odds ratios for the 
SOFAhem score were higher and the P- values lower.
4  | DISCUSSION
Whereas most previous studies on the prognosis of hematology pa-
tients at the ICU only reported on the predictive value of parameters 
available on ICU admission, the current study also evaluated prognos-
tic parameters after 3 days of ICU treatment using the classical and 
a modified SOFA score. The main findings of the present study are 
consecutively discussed in the sections below.
Our findings confirm that the prognosis in hematological pa-
tients is primarily determined by severity of illness, rather than 
underlying disease specific characteristics.3,24,25 In this study, mor-
tality was also associated with higher organ failure scores on ad-
mission, as well as inotropic/vasopressor therapy and mechanical 
ventilation. Although some studies reported that disease charac-
teristics were not associated with ICU mortality, other studies re-
ported a poor prognosis in patients after allogeneic SCT,5,26,27 In 
the present study, a higher mortality was seen in patients who had 
received an allogeneic SCT prior to ICU admission. This subgroup 
of patients represented only a minority (24%) of our population, as 
was the case in other studies.
Patients without a stem cell transplantation compared to patients 
with an autologous stem cell transplantation also had a worse out-
come. This group reflects the patients with acute leukemia, who have 
a higher mortality rate than patients without leukemia. Some prior 
studies also described an association between acute myeloid leukemia 
(AML) and a worse outcome.28,29 Analysis of aggregated data across 
multiple institutions may provide more insight into the prognosis of 
this patient subgroup. Such a national study has recently been per-
formed in the Netherlands, and its results are eagerly awaited (per-
sonal communication).
Patient characteristics Total (n=149)
ICU survivors  
(n=72; 48%)




Any SOFA score >15 in first week
Yes 44 30% 12 17% 32 43% 73 <.001
No 103 70% 60 83% 43 57% 42
Any SOFAhem score >7 in first week
Yes 104 70% 39 54% 65 86% 62 <.001
No 44 30% 33 46% 11 14% 25
Invasive mechanical ventilation
Yes 98 66% 33 46% 65 84% 66 <.001
No 51 34% 39 54% 12 16% 24
Vasopressor/inotropic medication
Yes 99 66% 30 42% 69 90% 70 <.001
No 50 34% 42 58% 8 10% 16
Renal replacement therapy
Yes 21 14% 7 10% 14 18% 67 .16
No 128 86% 65 90% 63 82% 49
Bacteriemia
Yes 56 38% 21 29% 35 46% 63% .04
No 93 62% 51 71% 42 54% 45%
Resuscitation
Yes 25 17% 3 4% 22 29% 88% <.001
No 124 83% 69 96% 55 71% 44%
ICU duration (days, median [IQR]) 4 (2- 10) 4 (1- 13) 4 (2- 9) .29
SCT, stem cell transplantation; CT, chemotherapy; IQR, interquartile range; SOFAhem max, highest SOFAhem score in first week; APACHE, acute physiology 
and chronic health evaluation; ICU, intensive care unit; SOFA, sequential organ failure assessment.
TABLE  2  (Continued)









(n=50; 49%) ICU mortality (%) P- value
Trend in SOFA
Decreased 30 29% 21 40% 9 18% 30
Unchanged 44 43% 19 36% 25 50% 57 .03
Increased 29 28% 13 24% 16 32% 55 .07
Trend in SOFAhem
Decreased 28 27% 21 40% 7 14% 25
Unchanged 51 50% 24 45% 27 54% 53 .02
Increased 24 23% 8 15% 16 32% 67 .005
Trend:	decreased	or	 increased	was	defined	as	≥2	points	change	compared	to	the	admission	SOFA/
SOFAhem score and the SOFA/SOFAhem score on day 3; n.s., non- significant; ICU, intensive care unit; 
SOFA, sequential organ failure assessment.
TABLE  3 Effect of trend in SOFA and 
SOFAhem score on ICU mortality
Odds ratio 95% CI P- value
Stem cell transplantation (SCT)
Autologous 1
No 2.72 1.03- 7.20 .04
Non- myeloablative allogeneic 3.82 1.05- 13.91 .04
Myeloablative 4.86 1.30- 18.13 .02
Invasive mechanical ventilation 6.40 2.96- 13.84 <.001
Bacteriemia 2.02 1.03- 3.99 .04
Vasopressor/inotropic medication 12.08 5.06- 28.80 <.001
Renal replacement therapy 2.06 0.78- 5.45 .14
Resuscitation 9.20 2.62- 32.34 <.001
APACHE II 1.15 1.08- 1.23 <.001
SOFA score day 1 1.31 1.16- 1.47 <.001
SOFAhem day 1 1.33 1.15- 1.54 <.001
SOFA max in first week 1.39 1.23- 1.57 <.001
SOFAhem max in first week 1.39 1.21- 1.60 <.001
Trend in SOFA score between day 1 and 3
Decreased 1
Increased 2.87 0.99- 8.37 .05
Unchanged 3.07 1.15- 8.20 .03
Trend in SOFAhem score between day 1 and 3
Decreased 1
Increased 6 1.80- 20.02 .04
Unchanged 3.38 1.22- 9.33 .02
ICU duration 1 0.99- 1.01 .99
Disease status
Partial or complete remission 1
Previously untreated 0.87 0.42- 1.8 .71
Progression (refractory and relapse) 1.30 0.55- 3.09 .55
Chemotherapy in last 30 d 0.76 0.38- 1.52 .44
Graft- vs - host disease 1.48 0.57- 3.86 .43
Neutropenia on ICU admission 1.30 0.69- 2.54 .39
CI, confidence interval; APACHE, acute physiology and chronic health evaluation; ICU, intensive care 
unit; SOFA, sequential organ failure assessment.
TABLE  4 Univariable analysis of factors 
associated with ICU mortality
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In line with most other studies, no difference in mortality in pa-
tients with neutropenia or patients with neutropenia recovery during 
ICU stay was seen. Some studies, although, did find higher mortality 
in patients with neutropenia or neutropenia recovery at the ICU.30,31
Furthermore, the change in SOFA score offers important addi-
tional prognostic information to help in this decision- making process 
to continue or discontinue treatment during such an ICU trial.3,8,10 
Patients with a deterioration of SOFA or SOFAhem score have a poor 
prognosis, and the trend in SOFA and SOFAhem score is independently 
related to mortality in our population of hematological patients admit-
ted to the ICU.
The observation that the odds ratios for the SOFAhem score are 
higher than for the SOFA score in the multivariable analysis and the 
P- values are lower even supports our view that the SOFAhem score 
was stronger related with mortality than the classical SOFA score. In 
hematological patients, neither the coagulation nor the neurological 
parameters are thus contributive because thrombocytopenia does not 
have to be an expression of the severity of illness, but is likely to be 
at least partly, an expression of the underlying hematological disease.
The conclusions of other studies that the neurological component 
can also be omitted were confirmed in this patient group.22,23
Despite the improvement in predictive power using the SOFAhem 
score compared to the traditional SOFA score, the trend in SOFAhem 
score is however still not an absolute decisive factor whether to 
continue treatment or not, as even in the poor risk group with an 
increasing SOFAhem score, about 30% of the patients survive their 
intensive care stay. However, the trend in SOFAhem score can aid 
in decision- making, taking into account all other clinically relevant 
information, and seems to perform better than the traditional SOFA 
in this respect.
5  | LIMITATIONS
This study has some limitations. First, this is a retrospective single 
center study. Admission policies and decision- making regarding re-
suscitation may be center specific, so patient characteristics in our 
population may differ from other centers. This may decrease the gen-
eralizability of our findings.
Second, in a significant number of patients (46/149), data to cal-
culate the SOFAhem score on day 3 were not available, either due to 
missing results, death of the patients, or discharge to the ward before 
a second SOFA score could be determined. Therefore, the SOFA trend 
could not be analyzed for all included patients.
Third, our population included patients with a mix of different 
hematological diseases. Conclusions may be different for certain 
subgroups. These subgroups were too small to perform multivariable 
analysis.
6  | CONCLUSIONS
In patients with hematological malignancies admitted to the ICU, 
trends in SOFA or SOFAhem score are both suitable as prognostic 
parameters that could aid in decision- making regarding continua-
tion of care. In this study, an unchanged or increased SOFAhem and 
unchanged SOFA score between days 1 and 3 is independently as-
sociated with mortality in ICU patients with hematological malignan-
cies. The trend in the modified hematological SOFA score omitting 
the neurological and hematological component probably is stronger 
related to mortality compared to the classical score and can be used 
in daily practice. It seems promising as an independent predictor of 
TABLE  5 Multivariable logistic regression analyses for trend in SOFAhem and SOFA score corrected for consecutively APACHE, invasive 
mechanical ventilation (MV), and vasopressor/inotropic medication (INO)
Odds ratio 95% CI P- value Odds ratio 95% CI P- value
APACHE 1.21 1.10- 1.33 <.001 APACHE 1.17 1.08- 1.27 <.001
Trend in SOFAhem Trend in SOFA
Decreasing 1 Decreasing 1
Increasing 17.64 3.74- 83.13 <.001 Increasing 5.77 1.63- 20.48 .007
Stable 7.88 2.18- 28.48 .002 Stable 4.68 1.50- 14.63 .008
MV 5.69 2.10- 15.45 .001 MV 5.25 1.97- 13.97 .001
Trend in SOFAhem Trend in SOFA
Decreasing 1 Decreasing 1
Increasing 8.02 2.19- 29.42 .002 Increasing 3.95 1.24- 12.59 .02
Stable 4.6 1.55- 13.68 .006 Stable 3.65 1.29- 10.37 .015
INO 18.18 5.23- 63.17 <.001 INO 15.97 4.76- 53.60 <.001
Trend in SOFAhem Trend in SOFA
Decreasing 1 Decreasing 1
Increasing 6.06 1.59- 23.06 .008 Increasing 2.75 0.83- 9.14 .099
Stable 6.11 1.86- 20.11 .003 Stable 4.2 1.33- 13.29 .015
MV, invasive mechanical ventilation; INO, vasopressor/inotropic medication; APACHE, acute physiology and chronic health evaluation; SOFA, sequential 
organ failure assessment.
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mortality in our population of hematological patients admitted to the 
ICU. Further large prospective studies are needed to confirm these 
preliminary findings.
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